Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

Drug interaction potential of resveratrol.

Detampel P, Beck M, Krähenbühl S, Huwyler J.

Drug Metab Rev. 2012 Aug;44(3):253-65. doi: 10.3109/03602532.2012.700715. Review.

PMID:
22788578
2.

Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence.

Sproule BA, Naranjo CA, Brenmer KE, Hassan PC.

Clin Pharmacokinet. 1997 Dec;33(6):454-71. Review.

PMID:
9435993
3.

Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.

Chan WK, Delucchi AB.

Life Sci. 2000 Nov 10;67(25):3103-12.

PMID:
11125847
4.

The red wine polyphenol resveratrol reduces polycyclic aromatic hydrocarbon-induced DNA damage in MCF-10A cells.

Leung HY, Yung LH, Shi G, Lu AL, Leung LK.

Br J Nutr. 2009 Nov;102(10):1462-8. doi: 10.1017/S0007114509990481.

PMID:
19811694
5.

Resveratrol in cholesterol metabolism and atherosclerosis.

Voloshyna I, Hussaini SM, Reiss AB.

J Med Food. 2012 Sep;15(9):763-73. doi: 10.1089/jmf.2012.0025. Review.

PMID:
22856383
7.

[Advance of studies on effect of resveratrol on activity of cytochrome P450].

Lu Y, Huang ZJ, Yuan H.

Zhongguo Zhong Yao Za Zhi. 2013 Mar;38(5):653-6. Review. Chinese.

PMID:
23724668
8.

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update.

Spina E, Santoro V, D'Arrigo C.

Clin Ther. 2008 Jul;30(7):1206-27. Review.

PMID:
18691982
9.

Commentary on 'resveratrol commonly displays hormesis: occurrence and biomedical significance' by Calabrese et al.

Das DK.

Hum Exp Toxicol. 2010 Dec;29(12):1016-7. doi: 10.1177/0960327110383626.

PMID:
21115560
10.

Influence of lipophilicity on the interactions of hydroxy stilbenes with cytochrome P450 3A4.

Regev-Shoshani G, Shoseyov O, Kerem Z.

Biochem Biophys Res Commun. 2004 Oct 15;323(2):668-73.

PMID:
15369802
11.

Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.

Zhou S, Yung Chan S, Cher Goh B, Chan E, Duan W, Huang M, McLeod HL.

Clin Pharmacokinet. 2005;44(3):279-304. Review.

PMID:
15762770
12.

MDR- and CYP3A4-mediated drug-herbal interactions.

Pal D, Mitra AK.

Life Sci. 2006 Mar 27;78(18):2131-45. Review.

PMID:
16442130
13.

Resveratrol addiction: to die or not to die.

Shakibaei M, Harikumar KB, Aggarwal BB.

Mol Nutr Food Res. 2009 Jan;53(1):115-28. doi: 10.1002/mnfr.200800148. Review.

PMID:
19072742
15.

Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice.

Bailey DG, Dresser GK, Bend JR.

Clin Pharmacol Ther. 2003 Jun;73(6):529-37.

PMID:
12811362
16.

Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components.

Piver B, Berthou F, Dreano Y, Lucas D.

Toxicol Lett. 2001 Dec 15;125(1-3):83-91.

PMID:
11701226
17.

Application of mechanism-based CYP inhibition for predicting drug-drug interactions.

Zhou ZW, Zhou SF.

Expert Opin Drug Metab Toxicol. 2009 Jun;5(6):579-605. doi: 10.1517/17425250902926099. Review.

PMID:
19466877
18.

Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6.

Ereshefsky L, Riesenman C, Lam YW.

Clin Pharmacokinet. 1995;29 Suppl 1:10-8; discussion 18-9. Review.

PMID:
8846618
19.

Dietary flavonoids: effects on xenobiotic and carcinogen metabolism.

Moon YJ, Wang X, Morris ME.

Toxicol In Vitro. 2006 Mar;20(2):187-210. Review.

PMID:
16289744
20.

In vitro effects of natural prenyloxycinnamic acids on human cytochrome P450 isozyme activity and expression.

Genovese S, Epifano F, Curini M, Menger D, Zembruski NC, Weiss J.

Phytomedicine. 2011 May 15;18(7):586-91. doi: 10.1016/j.phymed.2010.10.017.

PMID:
21112752

Supplemental Content

Support Center